KR20070100368A - 내장통 치료용 옥시코돈의 사용 - Google Patents

내장통 치료용 옥시코돈의 사용 Download PDF

Info

Publication number
KR20070100368A
KR20070100368A KR1020077018905A KR20077018905A KR20070100368A KR 20070100368 A KR20070100368 A KR 20070100368A KR 1020077018905 A KR1020077018905 A KR 1020077018905A KR 20077018905 A KR20077018905 A KR 20077018905A KR 20070100368 A KR20070100368 A KR 20070100368A
Authority
KR
South Korea
Prior art keywords
oxycodone
pain
pharmaceutically acceptable
acceptable salt
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077018905A
Other languages
English (en)
Korean (ko)
Inventor
아스브요른 모어 드류즈
라르 아렌트 닐센
Original Assignee
유로-셀띠끄 소시에떼 아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35871217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20070100368(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 유로-셀띠끄 소시에떼 아노님 filed Critical 유로-셀띠끄 소시에떼 아노님
Publication of KR20070100368A publication Critical patent/KR20070100368A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
KR1020077018905A 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용 Ceased KR20070100368A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64549005P 2005-01-18 2005-01-18
US60/645,490 2005-01-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020087029312A Division KR20080106991A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용

Publications (1)

Publication Number Publication Date
KR20070100368A true KR20070100368A (ko) 2007-10-10

Family

ID=35871217

Family Applications (10)

Application Number Title Priority Date Filing Date
KR1020077018905A Ceased KR20070100368A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020207031796A Ceased KR20200128451A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020227041445A Ceased KR20220165797A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020237042001A Ceased KR20230170811A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020127011713A Ceased KR20120089710A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020177004572A Ceased KR20170021905A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020087029312A Ceased KR20080106991A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020147018838A Ceased KR20140091782A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020217034339A Ceased KR20210131450A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020197035201A Ceased KR20190135557A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용

Family Applications After (9)

Application Number Title Priority Date Filing Date
KR1020207031796A Ceased KR20200128451A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020227041445A Ceased KR20220165797A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020237042001A Ceased KR20230170811A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020127011713A Ceased KR20120089710A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020177004572A Ceased KR20170021905A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020087029312A Ceased KR20080106991A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020147018838A Ceased KR20140091782A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020217034339A Ceased KR20210131450A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020197035201A Ceased KR20190135557A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용

Country Status (31)

Country Link
US (2) US20080200493A1 (https=)
EP (1) EP1838318B1 (https=)
JP (1) JP5049139B2 (https=)
KR (10) KR20070100368A (https=)
CN (1) CN101106996B (https=)
AP (1) AP2249A (https=)
AR (1) AR052880A1 (https=)
AT (2) ATE446092T1 (https=)
AU (1) AU2006207498B2 (https=)
BR (1) BRPI0606247A2 (https=)
CA (1) CA2595043C (https=)
CY (1) CY1109660T1 (https=)
DE (2) DE202006019887U1 (https=)
DK (2) DK1838318T3 (https=)
EA (1) EA013544B1 (https=)
ES (1) ES2333901T3 (https=)
HR (1) HRP20090679T1 (https=)
IL (1) IL184530A (https=)
ME (1) ME01066B (https=)
MX (1) MX2007007207A (https=)
MY (1) MY144471A (https=)
NO (1) NO338968B1 (https=)
NZ (1) NZ555852A (https=)
PL (1) PL1838318T3 (https=)
PT (1) PT1838318E (https=)
RS (1) RS51069B (https=)
SI (1) SI1838318T1 (https=)
TW (1) TWI432196B (https=)
UA (1) UA85471C2 (https=)
WO (1) WO2006077212A1 (https=)
ZA (1) ZA200705231B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY153249A (en) 2005-11-14 2015-01-29 Rinat Neuroscience Corp Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
CA2716424C (en) 2008-03-04 2015-04-28 Pfizer Limited Methods of treating chronic pain
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
KR101519192B1 (ko) * 2009-08-28 2015-05-11 리나트 뉴로사이언스 코프. 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
NZ717704A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
TWI685505B (zh) 2011-05-20 2020-02-21 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途
AU2012258980B8 (en) 2011-05-20 2017-06-15 H. Lundbeck A/S Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
PE20161439A1 (es) 2014-03-21 2017-01-26 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
CN113227140A (zh) 2019-01-08 2021-08-06 H.隆德贝克有限公司 使用抗cgrp抗体急性治疗和快速治疗头痛
KR20210124867A (ko) 2020-04-06 2021-10-15 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
WO1997035586A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US6992193B2 (en) * 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use

Also Published As

Publication number Publication date
TWI432196B (zh) 2014-04-01
ES2333901T3 (es) 2010-03-02
ME01066B (me) 2012-10-20
PL1838318T3 (pl) 2010-03-31
TW200637554A (en) 2006-11-01
AT9895U1 (de) 2008-05-15
AP2007004057A0 (en) 2007-08-31
NO20074174L (no) 2007-10-17
DE202006019887U1 (de) 2007-07-26
KR20080106991A (ko) 2008-12-09
EP1838318B1 (en) 2009-10-21
KR20210131450A (ko) 2021-11-02
ZA200705231B (en) 2008-06-25
HK1107933A1 (en) 2008-04-25
CY1109660T1 (el) 2014-08-13
RS51069B (sr) 2010-10-31
AU2006207498A1 (en) 2006-07-27
KR20230170811A (ko) 2023-12-19
AR052880A1 (es) 2007-04-11
BRPI0606247A2 (pt) 2009-06-09
DE602006009899D1 (de) 2009-12-03
KR20190135557A (ko) 2019-12-06
ATE446092T1 (de) 2009-11-15
NZ555852A (en) 2010-01-29
IL184530A (en) 2015-01-29
CA2595043A1 (en) 2006-07-27
US20150190393A1 (en) 2015-07-09
IL184530A0 (en) 2007-10-31
KR20170021905A (ko) 2017-02-28
MX2007007207A (es) 2007-08-15
WO2006077212A1 (en) 2006-07-27
EA013544B1 (ru) 2010-06-30
MY144471A (en) 2011-09-30
CA2595043C (en) 2013-11-19
EA200701541A1 (ru) 2008-02-28
JP2008526927A (ja) 2008-07-24
DK200700207U1 (da) 2007-08-24
SI1838318T1 (sl) 2010-02-26
CN101106996B (zh) 2013-10-23
NO338968B1 (no) 2016-11-07
KR20200128451A (ko) 2020-11-12
AU2006207498B2 (en) 2009-11-19
DK1838318T3 (da) 2010-01-04
US9271974B2 (en) 2016-03-01
KR20140091782A (ko) 2014-07-22
HRP20090679T1 (hr) 2010-01-31
EP1838318A1 (en) 2007-10-03
JP5049139B2 (ja) 2012-10-17
KR20120089710A (ko) 2012-08-13
DK200700207U3 (da) 2007-09-28
UA85471C2 (ru) 2009-01-26
KR20220165797A (ko) 2022-12-15
US20080200493A1 (en) 2008-08-21
PT1838318E (pt) 2009-12-15
AP2249A (en) 2011-07-18
CN101106996A (zh) 2008-01-16

Similar Documents

Publication Publication Date Title
US9271974B2 (en) Use of oxycodone for treating visceral pain
KR20070107805A (ko) 옥시코돈 및 날록손 함유 제형
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
EA030310B1 (ru) Гидроморфон и налоксон для лечения боли и индуцированного опиоидами синдрома дисфункции кишечника
KR20250145673A (ko) 통증 완화에 유용한 요법 및 조성물
HK1107933B (en) Use of oxycodone for treating visceral pain
EP3870175A1 (en) Oral aminodihydrophthalazinedione compositions and their use the treatment of non-viral hepatitis
AU2017276288A1 (en) Reducing drug liking in a subject

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20070817

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20080529

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20080930

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20080529

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20081030

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20080930

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20100831

Appeal identifier: 2008101011515

Request date: 20081030

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20081128

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20081128

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20081030

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20080728

Patent event code: PB09011R02I

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20090105

Patent event code: PE09021S01D

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial

Comment text: Report of Result of Re-examination before a Trial

Patent event code: PB06011S01D

Patent event date: 20091119

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20081030

Effective date: 20100831

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20100901

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20081030

Decision date: 20100831

Appeal identifier: 2008101011515